BrightSpring Health Services (BTSG) is back in focus after analysts raised earnings estimates, citing better cash flow trends and steady demand for its home-based care services across pharmacy and provider offerings.

The recent upward revisions in earnings estimates come alongside strong share price momentum, with a 28.1% 30 day share price return and a 60.6% year to date share price return. The 1 year total shareholder return is 159.1%, suggesting sentiment has improved materially over the past year.

If you are looking for more opportunities in healthcare and technology driven care models, this is a good moment to broaden your search and check out 37 healthcare AI stocks

With the stock at $61.68, very close to the $61.40 analyst price target but trading at an estimated 57% discount to intrinsic value, the key question is whether this is a genuine opportunity or if the market is already accounting for future growth in its current pricing.

Most Popular Narrative: 12.6% Undervalued

BrightSpring Health Services has a narrative fair value of $70.59 versus the last close at $61.68. This frames the stock as modestly undervalued and puts extra weight on how its business mix and margin story are understood.

The real business is not home health. It is pharmacy.

Roughly 80% of revenue comes from specialty and institutional pharmacy services:

• Infusion therapies delivered at home (oncology, autoimmune, IV antibiotics)

• Long-term care pharmacy services in assisted living and nursing facilities

• Specialty drug distribution for chronic and rare disease patients

This is where the structural moat exists.

Patients are not “customers” in the retail sense, they are clinically managed cases. Once a patient enters an infusion or specialty pharmacy program, switching providers is rare because:

• Treatment continuity is medically sensitive

• Coordination with nurses and physicians is embedded

• Insurance authorization is complex and sticky

• Logistics (cold chain, dosing schedules) are specialized

This creates low churn, recurring revenue, and embedded payer relationships.

Curious what kind of revenue mix, margin path, and future profit multiple underpin that $70.59 fair value? The narrative leans on a pharmacy heavy model, rising profitability, and a premium earnings profile that looks very different to a traditional home health stock.

Result: Fair Value of $70.59 (UNDERVALUED)

However, this hinges on pharmacy margins and cash generation holding up, and any setback in deleveraging or in the pace of KKR’s exit could quickly pressure that valuation story.

Another View: Rich Earnings Multiple Raises Questions

The narrative fair value suggests BrightSpring is modestly undervalued, yet the current P/E of 74.2x stands well above the estimated fair ratio of 35.3x, the US Healthcare industry average of 23.2x, and the peer average of 20.5x. That gap points to meaningful valuation risk if sentiment cools.

For a closer look at how this pricing compares with peers and the fair ratio, see the valuation breakdown, including the underlying earnings assumptions, in our See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With sentiment clearly mixed, this is the moment to look at the underlying data yourself and decide how comfortable you are with the trade off between growth expectations and valuation risk. To help pressure test both sides of the story, start with the 3 key rewards and 1 important warning sign

Looking for more investment ideas?

Do not stop with a single stock. Use this momentum to widen your watchlist and uncover other opportunities that fit your style before the crowd gets there.

• Target potential mispricings by checking companies filtered as 46 high quality undervalued stocks
• Prioritize resilience by focusing on businesses highlighted in the 62 resilient stocks with low risk scores
• Get ahead of the market by scanning the screener containing 22 high quality undiscovered gems

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.